This site is intended for healthcare professionals

Tecartus demonstrates high response rate in adults with relapsed or refractory B-cell acute lymphoblastic leukemia.- Kite/Gilead

Read time: 2 mins
Last updated:8th Jun 2021
Published:6th Jun 2021
Kite, a Gilead Company announced results from the primary analysis of ZUMA-3, a global, multicenter, single-arm, open-label Phase 1/II study evaluating its chimeric antigen receptor (CAR) T-cell therapy Tecartus (brexucabtagene autoleucel)(KTE 19) in adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Condition: B-Cell Acute Lymphoblastic Leukemia
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest